Cardiac monitor maker Kestra's Q2 revenue beats estimates

Kestra Medical Technologies

11/12/2025 21:11

Overview

Wearable medical device firm's fiscal Q2 revenue rose 53%, beating analyst expectations

Adjusted EBITDA loss for fiscal Q2 beat analyst estimates

Outlook

Kestra increases FY26 revenue guidance to $91 mln, up from $88 mln

Company focuses on expanding commercial organization and wearable defibrillator market

Result Drivers

MARKET EXPANSION - Revenue growth driven by higher market share and WCD market expansion

GROSS MARGIN IMPROVEMENT - Gross margin expanded to 50.6% due to volume leverage and higher in-network patient mix

OPERATIONAL PROGRESS - Progress in commercial expansion and revenue cycle management supported results

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
Beat
$22.57 mln
$20.70 mln (6 Analysts)
Q2 EPS
-$0.64
Q2 Adjusted EBITDA
Beat
-$19.68 mln
-$20.56 mln (6 Analysts)
Q2 Gross Profit
$11.42 mln
Q2 Income from Operations
-$31.76 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"

Wall Street's median 12-month price target for Kestra Medical Technologies Ltd is $28.00, about 14.2% above its December 10 closing price of $24.52

Press Release: ID:nGNXbdHzb2

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)